Both the parties have decided to fund a Phase 1 trial investigating OSI-906 as a single agent and in conjunction with the proteasome inhibitor bortezomib to treat relapsed multiple myeloma.
Multiple Myeloma Research Consortium (MMRC) will organize the trial to speed up the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.
The preclinical models of myeloma support a role for OSI-906 as a prominent therapeutic approach to the treatment of multiple myeloma.
MMRF and MMRC founder and CEO Kathy Giusti said as they enter into more of these collaborations with their biopharmaceutical partners, they are beginning to see the potential of the MMRF Clinical Fund project come to fruition as compounds that may have not been considered before are now being studied in myeloma.